Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

5.3%

4 terminated out of 75 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

4%

3 trials in Phase 3/4

Results Transparency

25%

4 of 16 completed with results

Key Signals

4 with results80% success

Data Visualizations

Phase Distribution

70Total
Not Applicable (2)
Early P 1 (5)
P 1 (48)
P 2 (12)
P 3 (2)
P 4 (1)

Trial Status

Unknown27
Completed16
Recruiting16
Active Not Recruiting5
Terminated4
Not Yet Recruiting4

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (75)

Showing 20 of 20 trials
NCT06131801Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

NCT06742996Phase 3Recruiting

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT05412290Phase 1Active Not RecruitingPrimary

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

NCT04088864Phase 1CompletedPrimary

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

NCT07584889Phase 1RecruitingPrimary

Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies

NCT06662227Early Phase 1SuspendedPrimary

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

NCT07093073Phase 1RecruitingPrimary

Clinical Study of U01(ssCART-19) in Patients With B-Cell Lymphoma

NCT06544265Phase 1RecruitingPrimary

SynKIR-310 for Relapsed/Refractory B-NHL

NCT03478514Phase 2Active Not Recruiting

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

NCT05332054Enrolling By Invitation

Long-Term Follow-up Study

NCT00586391Phase 1Active Not RecruitingPrimary

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

NCT06213311Phase 2RecruitingPrimary

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

NCT07166549Phase 1Not Yet Recruiting

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

NCT07270835Phase 4Recruiting

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

NCT06485076Not ApplicableRecruiting

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

NCT07198373Not Yet RecruitingPrimary

Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma

NCT04018248Phase 1Completed

BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)

NCT07162571Phase 1Not Yet Recruiting

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

NCT07101913Active Not Recruiting

Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma.

NCT06976437Early Phase 1RecruitingPrimary

A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

Scroll to load more

Research Network

Activity Timeline